Experience

Davis Polk advised the underwriters in connection with an initial public offering of 9,250,000 shares of common stock of Alector, Inc. at $19.00 per share, for total gross proceeds of $175…

Davis Polk is advising Nutrisystem, Inc. on its $1.4 billion acquisition by Tivity Health, Inc. The transaction, which is expected to close in the first quarter of 2019, is subject to…

Davis Polk is advising Mereo BioPharma Group plc on its combination with OncoMed Pharmaceuticals, Inc. The transaction, which is subject to customary closing conditions and the approval of…

Davis Polk advised the book-running manager and representative of the underwriters in connection with the initial public offering by Taiwan Liposome Company, Ltd. of American Depositary…

Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the approximately $225 million initial public offering by Orchard Therapeutics…

Davis Polk is advising Novo Nordisk on its $145 million acquisition of the U.S. and Canadian rights to Macrilen from Strongbridge Biopharma Plc. Novo Nordisk will also acquire newly issued…

Davis Polk advised the representatives of the underwriters in connection with the $50 million initial public offering of 6,250,000 ordinary shares of Gamida Cell Ltd. The ordinary…

Davis Polk advised the underwriters in connection with the $90 million initial public offering of common stock by Kodiak Sciences Inc. The common stock is listed on the NASDAQ Global Market…

Davis Polk advised the representatives of the several underwriters in connection with the $60 million initial public offering of common stock of Constellation Pharmaceuticals, Inc. The…

Davis Polk advised the underwriters in connection with an initial public offering of 8,203,332 shares of common stock of Allakos Inc. at $18.00 per share (which includes the exercise in…